BCTX
Income statement / Annual
Last year (2024), BriaCell Therapeutics Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, BriaCell Therapeutics Corp.'s net income was -$4.79 M.
See BriaCell Therapeutics Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
07/31/2024 |
07/31/2023 |
07/31/2022 |
07/31/2021 |
07/31/2020 |
07/31/2019 |
07/31/2018 |
07/31/2017 |
07/31/2016 |
07/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$82,583.00 |
$15,529.00 |
$15,141.00 |
$15,573.00 |
$13,991.00 |
$14,273.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$82,583.00 |
-$15,529.00 |
-$15,141.00 |
-$15,573.00 |
-$13,991.00 |
-$14,273.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$26.75 M
|
$15.34 M
|
$8.02 M
|
$1.32 M
|
$2.22 M
|
$3.74 M
|
$2.39 M
|
$1.71 M
|
$723,428.00
|
$105,824.00
|
| General & Administrative
Expenses |
$6.15 M
|
$7.94 M
|
$7.27 M
|
-$3.67 M
|
-$1.37 M
|
-$932,169.26
|
-$1.05 M
|
$876,162.00
|
$942,018.00
|
$1.33 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.15 M
|
$7.94 M
|
$7.27 M
|
-$3.67 M
|
-$1.37 M
|
-$932,169.26
|
-$1.05 M
|
$876,162.00
|
$942,018.00
|
$1.33 M
|
| Other Expenses |
$0.00 |
$0.00 |
-$15.29 M |
-$1.33 M |
-$2.24 M |
-$3.75 M |
-$312,917.04 |
$290.00 |
$1,790.00 |
$565.00 |
| Operating Expenses |
$32.73 M |
$23.27 M |
-$3,388.00 |
-$3.69 M |
-$1.38 M |
-$946,423.36 |
-$1.07 M |
$2.58 M |
$1.67 M |
$1.44 M |
| Cost And Expenses |
$32.81 M |
$23.27 M |
-$3,388.00 |
-$3.69 M |
-$1.38 M |
-$946,423.36 |
-$1.07 M |
$2.58 M |
$1.67 M |
$1.44 M |
| Interest Income |
$0.00 |
$891,213.00 |
$136,731.00 |
$3,149.00 |
$39.48 |
$9,129.07 |
$12,273.00 |
$5,157.46 |
$3,627.32 |
$7,092.67 |
| Interest Expense |
$0.00 |
$0.00 |
$979.00 |
$46,095.00 |
$26,995.00 |
$23,816.00 |
$15,629.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$82,583.00
|
$15,271.00
|
$15,272.00
|
$15,256.00
|
$15,255.00
|
$14,254.00
|
$12,966.00
|
$232.68
|
$907.21
|
$434.31
|
| EBITDA |
-$4.77 M
|
-$30.67 M
|
-$15.13 M
|
-$8.69 M
|
-$3.97 M
|
-$6.67 M
|
-$4.96 M
|
-$3.22 M
|
-$2.18 M
|
-$1.80 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$28.02 M
|
$2.97 M
|
$3.74 M
|
-$6.84 M
|
-$85,097.00
|
$0.00
|
-$1.59 M
|
$634,113.00
|
$481,604.00
|
-$1.24 M
|
| Income Before Tax |
-$4.79 M |
-$20.30 M |
-$11.55 M |
$3.69 M |
$1.38 M |
$946,423.00 |
$1.07 M |
-$2.58 M |
-$1.70 M |
-$2.68 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$62,852.00 |
-$152,624.00 |
$30,730.00 |
$6.58 M |
-$72,250.96 |
$343,743.00 |
$1.59 M |
$638,592.00 |
$547,965.00 |
$2.05 M |
| Net Income |
-$4.79 M |
-$20.30 M |
-$11.58 M |
-$2.89 M |
$1.38 M |
$602,680.00 |
$1.07 M |
-$2.58 M |
-$1.70 M |
-$2.68 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.29 |
-1.3 |
-0.75 |
-0.64 |
1.94 |
1.04 |
2.49 |
-7.61 |
-5.88 |
-10.76 |
| EPS Diluted |
-0.29 |
-1.3 |
-0.75 |
-0.64 |
1.94 |
1.04 |
2.49 |
-7.32 |
-5.88 |
-10.76 |
| Weighted Average Shares
Out |
$16.45 M
|
$15.62 M
|
$15.49 M
|
$4.52 M
|
$713,889.00
|
$579,663.00
|
$427,814.00
|
$339,707.00
|
$288,443.00
|
$249,178.00
|
| Weighted Average Shares
Out Diluted |
$16.45 M
|
$15.62 M
|
$15.49 M
|
$4.52 M
|
$713,889.00
|
$579,663.00
|
$427,815.00
|
$352,979.00
|
$288,443.00
|
$249,178.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
